Literature DB >> 19473415

Survival in a cohort of patients with haemophilia at the haemophilia care center in Vienna, Austria, from 1983 to 2006.

S Reitter1, T Waldhoer, C Vutuc, K Lechner, I Pabinger.   

Abstract

Survival of patients with haemophilia is still a relevant issue of great interest. A survival analysis was conducted among 226 patients with haemophilia A and B (128 severe haemophiliacs), who were treated at the haemophilia care centre in Vienna. Information on mortality in our patient cohort was obtained from the Austrian Central Death Register. Overall, 96 of a total of 226 patients (42.5%) died between 1983 and 2006; 37 patients (38.5%) died due to HIV-infection, 15 due to HCV infection, 15 due to bleeding (15.6%, respectively) and 29 (30.2%) due to various other causes. The mortality of HIV-positive patients was 74.3% (n = 55) and that of HCV-positive patients was 40.4% (n = 55) in the analysed period. The patient mortality rates were compared with those of the general Austrian male population following adjustment for age and calendar period. We found that the cumulative relative survival of all patients was 0.694 (95% CI 0.614-0.767). The cumulative relative survival of patients with severe haemophilia (FVIII or IX level < or =1%) was 0.489 (0.394-0.579), but was normal (0.986; 95% CI 0.858-1.082) for patients with mild or moderate haemophilia (FVIII or IX level 2-50%). The survival rate was lowest in HIV-positive patients (0.287; 95% CI 0.186-0.398), but was also decreased to 0.874 (0.776-0.951) in HIV-negative patients. It can, therefore, be concluded that the survival of patients with severe haemophilia is still decreased compared to those with non-severe haemophilia and the general male population, regardless of HIV-infection.

Entities:  

Mesh:

Year:  2009        PMID: 19473415     DOI: 10.1111/j.1365-2516.2009.02029.x

Source DB:  PubMed          Journal:  Haemophilia        ISSN: 1351-8216            Impact factor:   4.287


  5 in total

1.  The health and economic burden of haemophilia in Belgium: a rare, expensive and challenging disease.

Authors:  Séverine Henrard; Brecht Devleesschauwer; Philippe Beutels; Michael Callens; Frank De Smet; Cedric Hermans; Niko Speybroeck
Journal:  Orphanet J Rare Dis       Date:  2014-03-21       Impact factor: 4.123

2.  Factors Associated with Compliance with the Treatment Protocol and Mortality in Adults with Hemophilia.

Authors:  Beatriz Mac Dowell Soares; Luiz Alberto Simeoni; Karlo Jozefo Quadros de Almeida; Jaqueline Lima de Souza; Aline Mizusaki Imoto; Melina Swain Braverman; Lucas Barbosa Bezerra; Alexandre Jorge Teixeira Ribeiro; Ana Maria Costa; Fábio Ferreira Amorim
Journal:  Patient Prefer Adherence       Date:  2020-11-20       Impact factor: 2.711

Review 3.  Mortality in congenital hemophilia A - a systematic literature review.

Authors:  Charles R M Hay; Francis Nissen; Steven W Pipe
Journal:  J Thromb Haemost       Date:  2021-01       Impact factor: 5.824

4.  Pharmacokinetic parameter driven outcomes model predicts a reduction in bleeding events associated with BAY 81-8973 versus antihemophilic factor (recombinant) plasma/albumin-free method in a Chinese healthcare setting.

Authors:  Rong Chen; Dmitry Gultyaev; Johanna Lister; Rong Han; Nan Hu; Jean Malacan; Alexander Solms; Parth Vashi; Jamie O'Hara; Shanlian Hu
Journal:  BMC Med Res Methodol       Date:  2022-08-05       Impact factor: 4.612

Review 5.  Therapeutic and routine prophylactic properties of rFactor VIII Fc (efraloctocog alfa, Eloctate®) in hemophilia A.

Authors:  Pratima Chowdary; Emma Fosbury; Anne Riddell; Mary Mathias
Journal:  J Blood Med       Date:  2016-09-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.